CEFTRIAXON Lagap 500 mg i.v. / 500 mg / 10 flacon(
7680685350022
CH-68535
J01DD04
08.01.
Reimbursement limitations:
ROCEPHIN2
• Traitement ultérieur dans la pratique ambulatoire de l'ostéomyélite, des abscès pulmonaires et de l'endocardite.
…
1 / 3
google
Details
- Product number
- 6853501
- CPT
- -
- Packaging group
- 10
- Unit
- Durchstechflasche(n)
- Composition
- ceftriaxonum 500 mg ut ceftriaxonum natricum, pro vitro corresp. natrium 41.5 mg.
Articles (1)
Ceftriaxon Lagap 500 mg i.v., Polvere per soluzione iniettabile
soluzione
10
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
500.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | WIZUS |
|
(N/A)
|
41.5 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 72.90
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/07/2025
Authorization holder
Lagap SA
6943 Vezia
Authorization information
- Swissmedic authorization number
- 68535
- Drug name
- Ceftriaxon Lagap, Polvere per soluzione iniettabile/per infusione
- Galenic form
- PULVII
- ATC Code
- J01DD04
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 24/11/2022
- Authorization expiration date
- 23/11/2027
- IT number
- 08.01.
- Domain
- Human medicine
Packaging details
- Description (FR)
- CEFTRIAXON Lagap 500 mg i.v. / 500 mg / 10 flacon(
- Description (DE)
- CEFTRIAXON Lagap 500 mg i.v. / 500 mg / 10 Durchst
- Market launch
- 24/11/2022
- Narcotic (BTM)
- No
Original drug
Rocephin, Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung
GTIN:
7680446250011
CHF 21.05